

Sunil Bansal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10221046/publications.pdf>

Version: 2024-02-01

9
papers

75
citations

1478505

6
h-index

1474206

9
g-index

10
all docs

10
docs citations

10
times ranked

89
citing authors

#	ARTICLE	IF	CITATIONS
1	C-Terminal Fragment, AÎ ² ₃₂ “37, Analogues Protect Against AÎ ² Aggregation-Induced Toxicity. ACS Chemical Neuroscience, 2016, 7, 615-623.	3.5	30
2	Antiplasmodial activity of short peptide-based compounds. RSC Advances, 2015, 5, 22674-22684.	3.6	8
3	TGFÎ ² Drives Metabolic Perturbations during Epithelial Mesenchymal Transition in Pancreatic Cancer: TGFÎ ² Induced EMT in PDAC. Cancers, 2021, 13, 6204.	3.7	8
4	C-Terminal Fragment, AÎ ² ₃₉ “42-Based Tetrapeptides Mitigates Amyloid-Î ² Aggregation-Induced Toxicity. ACS Omega, 2018, 3, 10019-10032.	3.5	7
5	Cholecystokinin Receptor Antagonist Improves Efficacy of Chemotherapy in Murine Models of Pancreatic Cancer by Altering the Tumor Microenvironment. Cancers, 2021, 13, 4949.	3.7	7
6	AÎ ² ₁ “42 C-terminus fragment derived peptides prevent the self-assembly of the parent peptide. RSC Advances, 2017, 7, 4167-4173.	3.6	6
7	Longitudinal metabolic alterations in plasma of rats exposed to low doses of high linear energy transfer radiation. Journal of Environmental Science and Health, Part C: Toxicology and Carcinogenesis, 2021, 39, 219-233.	0.7	4
8	An optimized method for the isolation of urinary extracellular vesicles for molecular phenotyping: detection of biomarkers for radiation exposure. Journal of Translational Medicine, 2022, 20, 199.	4.4	4
9	Safety and Pharmacokinetic Assessment of Oral Proglumide in Those with Hepatic Impairment. Pharmaceutics, 2022, 14, 627.	4.5	1